Products - Liver cancers | Topic | NICE

Showing 10 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
17 July 2024
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
25 March 2026
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
29 July 2026
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
29 October 2026
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC